We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, you'd have done very well indeed. So, the natural question for Medigene (ETR:MDG1) shareholders is whether they should be concerned by its rate of cash burn. The grim reality for shareholders is that operating revenue fell by 71% over the last twelve months, which is not what we